Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.250 -0.050 (-3.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Shares of Editas Medicine Are Lower This Morning
Incomplete data is disappointing investors after a long wait. 
Via The Motley Fool
Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress
Editas is working on a treatment for a blindness-causing genetic disorder. 
Via Investor's Business Daily
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
Via Benzinga
'Fast Money Halftime Report' Picks For September 13
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wells Fargo lowered the price target on General Motors Company (NYSE: 
Via Benzinga
3 Red-Hot Healthcare Stocks to Buy in September
These businesses are firing on all cylinders. 
Via The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
35 Stocks Moving In Monday's Mid-Day Session
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value... 
Via Benzinga
25 Stocks Moving in Monday's Pre-Market Session
Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X... 
Via Benzinga
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology
Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were... 
Via Benzinga
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
Editas could be an attractive acquisition candidate for the big vaccine maker. 
Via The Motley Fool
Why Editas Medicine Beat the Market on Monday
Another analyst ups his recommendation on the stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ: 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Keybanc boosted the price target for HubSpot, Inc. (NYSE: 
Via Benzinga
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Editas Medicine Stock Shows Improved Relative Strength Rating
A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Editas Stock Isn’t Worth Buying This Early Into Treatment Development
EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term. 
Via InvestorPlace
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
It's a good time to be a gene-editing company. 
Via The Motley Fool
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.